GlassScriptPhysician profile
Amber N Pepper
NPI 1013259407
$7,978.59
in general payments reported to CMS, 2019-2025
39 companies · $2,712 in 2025
The $2,712 reported for 2025 was more than what 78% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $129 · 2021: $160 · 2022: $357 · 2023: $858 · 2024: $3,227 · 2025: $2,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,805 · Consulting Fee: $1,195 · Travel and Lodging: $551 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,804.92 |
| Consulting Fee | $1,195.38 |
| Travel and Lodging | $551.10 |
| Education | $246.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,882.79 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $999.46 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $624.31 | 2019-2025 | Nucala, Trelegy Ellipta |
| Csl Behring | $515.83 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Regeneron Healthcare Solutions, INC. | $475.73 | 2019-2025 | Dupixent |
| Genzyme Corporation | $449.88 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $262.77 | 2023-2025 | Takhzyro, Cuvitru, Eohilia |
| Pfizer INC. | $237.22 | 2020-2025 | |
| Pharming Healthcare, INC. | $163.08 | 2022-2025 | Ruconest |
| Genentech USA, INC. | $157.47 | 2019-2025 | Xolair |
| Arcutis Biotherapeutics, INC. | $104.55 | 2025 | |
| Amgen INC. | $97.99 | 2024-2025 | Tezspire |
| Grifols USA, LLC | $96.66 | 2024-2025 | Xembify, Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $91.99 | 2022 | |
| Genentech, INC. | $83.54 | 2024 | Xolair |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $76.93 | 2019-2022 | |
| Lilly USA, LLC | $62.59 | 2025 | Ebglyss |
| Incyte Corporation | $58.25 | 2025 | Opzelura |
| Optinose US, INC. | $51.95 | 2022-2025 | |
| Adma Biomanufacturing LLC | $45.38 | 2024-2025 | |
| Abbvie INC. | $42.86 | 2023-2024 | |
| Shire North American Group INC | $42.64 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $42.45 | 2019 | |
| Gc Biopharma USA, INC. | $40.34 | 2025 | Alyglo |
| Hikma Pharmaceuticals USA | $38.47 | 2024-2025 | Ryaltris |
| Ionis Pharmaceuticals, INC. | $34.82 | 2025 | Dawnzera |
| Greer Laboratories, INC. | $30.27 | 2024 | Oralair |
| Kaleo, INC. | $30.05 | 2019-2023 | Auvi-Q |
| Merck Sharp & Dohme LLC | $23.68 | 2025 | Capvaxive |
| Leo Pharma INC. | $23.51 | 2023 | Adbry |
| Ars Pharmaceuticals Operations, INC. | $21.83 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $20.53 | 2025 | Nemluvio |
| Cycle Pharmaceuticals INC | $17.88 | 2025 | Sajazir |
| Alk-Abello, INC | $16.95 | 2023 | Grastek, Ragwitek, Odactra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.43 | 2021 | |
| Organon LLC | $2.51 | 2025 | Vtama |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Pepper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.